Analystreport

Blueprint Medicines Co. (NASDAQ: BPMC) had its price target raised by analysts at UBS Group AG from $88.00 to $129.00. They now have a "neutral" rating on the stock.

Blueprint Medicines Corporation  (BPMC) 
Last blueprint medicines corporation earnings: 2/13 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: blueprintmedicines.com